| Lee et al.10 (2015) Seoul, Korea |
|
|
0.2 mL of maternal colostrum was administered via oropharynx, 0.1 mL into the right and left oral mucosa every 3 hours after 48 to 96 hours of life, for 72 hours, regardless of the child’s enteral feeding. |
0.2 mL of sterile water was administered, according to the oropharyngeal colostrum immunotherapy protocol. |
Low risk |
|
| Rodriguez et al.8 (2011) Midwest, EUA |
|
|
0.2 mL of maternal colostrum was administered via oropharynx, 0.1 mL into the right and left oral mucosa before 48h of life every 2h for 48h, enteral feeding was started after the protocol was completed. |
0.2 mL of sterile water was administered, according to the oropharyngeal colostrum immunotherapy protocol. |
Some concern |
|
| Sohn et al.7 (2015) California, USA |
|
|
0.2 mL of maternal colostrum was administered into the oral cavity (0.1 mL on each side of the oral cavity) every 2 hours for 46 hours, regardless of whether the child was receiving trophic food. |
Control group received routine care. |
High risk |
|
| Glass et al.11, (2017) Pennsylvania, USA |
|
|
0.2 mL of maternal colostrum was administered to the oral mucosa with a swab every 3 hours for 2 to 7 days. |
0.2 mL of sterile water was administered, according to the oropharyngeal colostrum immunotherapy protocol. |
High risk |
|
| Romano-Keeler et al.21, (2016) Nashville, Tennessee, USA |
|
|
0.2 mL of maternal colostrum was administered, started in the first 48 hours of life, 0.1 mL on each side of the oral mucosa every 6 hours for 5 days. |
Control group received routine care. |
High risk |
|
| Zhang et al.6, (2017) Shanghai, China |
|
|
0.2 mL of maternal colostrum was administered, 0.1 mL on each side of the oral mucosa with a constant speed of at least 20 seconds over 4 hours, for seven days. |
0.2 mL of saline solution was administered according to the oropharyngeal administration protocol. |
Some concern |
|
| Abd-Elgawad et al.9, (2019) Egypt |
|
|
0.2 mL of maternal colostrum was administered to the oral mucosa, involving the oropharynx, tongue, and cheeks every 2 or 4 hours, during the pre-feeding period. When infants met the criteria for starting enteral feeding, 0.2 mL of the mother’s colostrum was administered to the oropharynx, tongue, and cheeks 5 minutes before gavage until Rn reached complete enteral feeding. |
Nothing was administered during the pre-feeding period in the regular gavage group (control). The mother’s colostrum or breast milk was administered via tube when the premature infants adjusted to the criteria to start enteral feeding. |
Some concern |
|
| Sharma et al.12, (2020) India |
|
|
Oropharyngeal administration of 0.2 mL of maternal colostrum to the oral mucosa, 0.1 mL directed to the oropharynx on both sides. Started after 24 hours of life every 2 hours for 72 hours, regardless of the infant’s enteric feeding status. |
Control group newborns received routine care. |
High |
|
| Shiney Easo et al.23 (2018) Kuwait |
|
|
0.1 mL of colostrum or fresh or chilled breast milk was administered slowly to the posterior end of the oral cavity, drop by drop over 30 s. Procedure was repeated on the opposite side. Therapy was started right after birth, every 4 hours, and continued until reaching complete enteral feeding. |
Control group received 0.2 mL of sterile water applied in the same way and frequency as the intervention group. Started in the first 6 hours of life. |
Some concern |
|
| Ferreira et al.22 (2019) Brazil |
|
|
0.2 mL of maternal colostrum was administered in the first 48 or 72 hours of life every 2 hours for 48 hours, 0.1 mL to the right oral mucosa, and 0.1 mL to the left. |
0.2 mL of sterile water was administered, according to the oropharyngeal colostrum immunotherapy protocol. |
Some concern |
|
Thumbnail
Thumbnail
